Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
SS-31 (Szeto-Schiller peptide 31) is a synthetic mitochondrial-targeted tetrapeptide developed by Hazel Szeto and Peter Schiller in the early 2000s. SS-31 peptide research has produced one of the most well-developed mechanistic accounts of any small peptide examined in mitochondrial biology, with primary published work centered on the peptide’s high-affinity interaction with cardiolipin — an anionic phospholipid expressed almost exclusively on the inner mitochondrial membrane.
The compound is one member of the broader Szeto-Schiller (SS) peptide family, distinguished by an alternating cationic-aromatic structural motif that confers selective accumulation within the inner mitochondrial membrane independently of membrane potential. The mitochondria-targeting property has made SS-31 a widely-used research tool for investigators studying oxidative phosphorylation, cardiolipin biology, ischemia-reperfusion injury, and mitochondrial bioenergetics across multiple organ systems.
This article reviews the published preclinical record on SS-31 research, its molecular mechanism of action centered on cardiolipin binding, and the laboratory considerations relevant to investigators. The body of literature now spans nearly two decades and incorporates work from multiple independent laboratories, providing a relatively mature foundation for new mechanistic and translational investigations.
Molecular Profile
SS-31 carries the chemical structure D-Arg-Dmt-Lys-Phe-NH₂ (where Dmt is 2′,6′-dimethyltyrosine). The peptide is C-terminally amidated, contains the unnatural D-isomer of arginine at the N-terminus, and incorporates the modified aromatic residue 2′,6′-dimethyltyrosine. Its molecular formula is C₃₂H₄₉N₉O₅ and molecular weight is approximately 639.79 Da.
The structural design of SS-31 reflects two engineering choices that confer its defining properties. The D-arginine prevents proteolytic degradation by mammalian peptidases, increasing the compound’s half-life relative to natural L-arginine-containing peptides. The alternating cationic-aromatic motif (positive charge alternating with aromatic side chains) is the structural feature responsible for inner-mitochondrial-membrane targeting and high-affinity cardiolipin binding.
SS-31 is water-soluble and is supplied as a lyophilized white powder produced by solid-phase peptide synthesis. The peptide does not require organic carrier solvents for aqueous preparation.
The chemistry also incorporates several features worth highlighting from a research-tool standpoint. The 2′,6′-dimethyltyrosine residue is an electron-rich aromatic amino acid that contributes both to mitochondrial targeting through hydrophobic interactions with cardiolipin acyl chains and to a reported scavenging activity for lipid-derived reactive species at the inner membrane. The phenylalanine at the C-terminus and the amidated C-terminal group reduce overall charge density and improve membrane permeability. Together these features produce a small molecule with the bioenergetic accessibility of a peptide and the membrane-targeting properties of a lipophilic small molecule — an unusual combination that helps explain SS-31’s utility as a research tool across diverse experimental systems.
Mechanism of Action
The mechanism of SS-31 is among the best characterized in the mitochondrial-targeted peptide literature. The peptide selectively accumulates in the inner mitochondrial membrane through electrostatic and hydrophobic interactions with cardiolipin, a tetra-acyl phospholipid that is required for cristae formation and that supports the assembly and function of multiple respiratory chain components.
The defining mechanistic study was published by Birk A.V., Liu S., Soong Y., et al. in the Journal of the American Society of Nephrology (2013), describing how SS-31 protects mitochondrial cristae during ischemia by binding cardiolipin and inhibiting the cardiolipin-peroxidase activity of cytochrome c. The binding of cytochrome c to cardiolipin under oxidative-stress conditions converts the protein from an electron carrier into a peroxidase, catalyzing cardiolipin peroxidation and initiating apoptotic cascades. SS-31 disrupts this conversion, preserving cardiolipin and cytochrome c function during ischemia-reperfusion stress.
A complementary line of work has established that SS-31 promotes recovery of mitochondrial respiration, restores ATP production, and preserves cristae membrane architecture in models of ischemia-reperfusion injury across renal, cardiac, and neural tissue.
Biophysical and structural studies have refined the cardiolipin-binding model considerably. Cardiolipin is unique among membrane phospholipids in carrying two phosphate groups and four acyl chains; this structure produces a localized region of high negative charge surface density that attracts cationic species. SS-31’s two positive charges (D-Arg and Lys), spaced by aromatic residues, appear well-matched to this surface topology. Importantly, the binding interaction does not depend on inner-membrane potential — distinguishing SS-31 from earlier mitochondrial-targeted molecules such as triphenylphosphonium-conjugated antioxidants, which require an intact membrane potential to accumulate. The membrane-potential independence is a critical experimental property because it allows SS-31 to localize to mitochondria even in tissue undergoing severe bioenergetic stress, when membrane potential is collapsed.
Key Research Areas
1. Cardiolipin Binding and Mitochondrial Bioenergetics
The foundational SS-31 peptide research established the cardiolipin-binding mechanism. Birk A.V., Liu S., Soong Y., et al. (2013), publishing in JASN, demonstrated that SS-31 binds cardiolipin with high affinity, protects cristae membrane architecture during renal ischemia, prevents mitochondrial swelling, and accelerates ATP recovery following an ischemic insult. A related 2014 review by Szeto H.H. in the British Journal of Pharmacology consolidated the cardiolipin-protective framework and positioned SS-31 as a first-in-class cardiolipin-protective compound.
Earlier biophysical work by Zhao K., Zhao G.M., Wu D., et al. (2004), publishing in the Journal of Biological Chemistry, characterized the cell-permeable antioxidant properties of the SS-peptide series and established that the alternating cationic-aromatic motif drives selective inner-membrane accumulation. Szeto H.H. and Liu S. (2018), in Archives of Biochemistry and Biophysics, provided an integrated review of cardiolipin-targeted peptides as bioenergetic research tools, summarizing biochemical, structural, and functional data accumulated over the prior decade. The cumulative literature now provides a relatively granular account of cardiolipin-peptide binding biophysics that is unusual for small synthetic peptides.
2. Ischemia-Reperfusion Preclinical Research
SS-31 has been investigated in preclinical ischemia-reperfusion injury models across multiple organ systems. In the heart, studies have examined the peptide in models of acute myocardial infarction and post-ischemic ventricular dysfunction. In the kidney, work by the Szeto laboratory and collaborators has examined SS-31 in renal ischemia-reperfusion and chronic kidney disease models. In the brain, investigations have examined the peptide in cerebral ischemia models. A consistent finding across these tissue systems is preservation of mitochondrial respiration, reduction in oxidative damage markers, and improved structural and functional outcomes in treated animals compared to vehicle controls.
Liu S., Soong Y., Seshan S.V., and Szeto H.H. (2014), publishing in American Journal of Physiology – Renal Physiology, reported that SS-31 protects endothelial mitochondria during renal ischemia and reduces subsequent microvascular rarefaction, inflammation, and fibrosis — extending the mechanistic narrative from acute mitochondrial protection to chronic structural remodeling outcomes. Min K., Smuder A.J., Kwon O.S., et al. have examined SS-31 in skeletal muscle ischemia-reperfusion paradigms, with comparable findings of preserved mitochondrial function and reduced oxidative injury. The breadth of organ systems in which the peptide has been examined reflects the universal role of mitochondrial bioenergetics across tissue contexts.
3. Heart Failure and Cardiac Bioenergetics Research
The cardiac literature on SS-31 has examined the peptide in heart failure models with preserved and reduced ejection fraction, in aging-associated cardiomyopathy, and in models of mitochondrial cardiomyopathy. Dai D.F., Chen T., Szeto H., et al. published findings in the Journal of the American College of Cardiology (2011) reporting that SS-31 administration to aged mice was associated with reduced age-related cardiac dysfunction, restored mitochondrial function in cardiomyocytes, and improvements in echocardiographic parameters compared to controls.
Sabbah H.N. and colleagues have published work examining SS-31 in canine models of advanced heart failure, reporting improvements in mitochondrial respiration, reduced reactive oxygen species output, and partial restoration of contractile function. Mechanistic studies in isolated cardiomyocytes by multiple groups have reported preservation of cristae architecture by electron microscopy, restored respiratory complex assembly, and improved coupling efficiency in mitochondria from SS-31-treated tissue compared to controls. The cardiomyopathy literature is one of the larger and more methodologically diverse subdomains of the broader SS-31 research portfolio.
4. Aging and Mitochondrial Dysfunction Research
A growing body of preclinical work has examined SS-31 in the context of mitochondrial dysfunction associated with aging. Investigators have published studies in skeletal muscle, cardiac, neural, and renal tissue from aged rodents reporting improvements in mitochondrial respiration capacity, reductions in oxidative damage markers, and changes in transcriptional signatures associated with mitochondrial biogenesis following peptide treatment.
Siegel M.P., Kruse S.E., Percival J.M., et al. (2013), publishing in Aging Cell, reported that mitochondrial-targeted peptide treatment rapidly improved mitochondrial energetics and skeletal muscle performance in aged mice — work that has been frequently cited as a foundational study in the SS-31 aging literature. More recent investigations by Campbell M.D., Duan J., Samuelson A.T., et al. have extended these findings using detailed proteomic and metabolomic profiling, reporting selective effects on respiratory complex assembly and electron flux in aged tissue.
For investigators studying related mitochondrial-targeted research peptides, MOTS-c represents a distinct class of mitochondrial-derived peptide with its own developing literature on metabolic regulation and mitonuclear communication. The two compounds operate through different mechanisms but together represent the leading examples of peptide-based mitochondrial research tools.
Comparative Research Landscape
SS-31 occupies a distinctive position within the broader landscape of mitochondrial-targeted research compounds, several of which provide useful comparators for experimental design and mechanistic interpretation.
Among other mitochondrial-targeted small molecules, MitoQ and similar triphenylphosphonium (TPP)-conjugated antioxidants accumulate in mitochondria through electrostatic attraction to the negative-inside membrane potential. This mechanism depends on intact bioenergetics and may fail in severely ischemic or depolarized mitochondria — precisely the conditions in which protective intervention is most needed. SS-31’s membrane-potential-independent localization through cardiolipin binding distinguishes it from this class and is a key reason it remains an active research tool. SkQ1 and related plastoquinone-TPP conjugates share the limitations of the TPP class but have their own published literature in aging and ischemia models.
Among peptide-based mitochondrial research compounds, MOTS-c (a 16-amino-acid peptide encoded within mitochondrial DNA) and humanin (a 24-amino-acid peptide also of mitochondrial origin) represent a fundamentally different category — mitochondrial-derived peptides released from mitochondria that act as systemic signaling molecules rather than as targeted bioenergetic interventions. SS-31, by contrast, is a synthetic compound designed to accumulate in mitochondria from the cytosol. The two categories are not interchangeable but are sometimes studied as complementary tools for dissecting different aspects of mitochondrial biology.
Within the broader Szeto-Schiller peptide family, related members including SS-02 and SS-20 share the alternating cationic-aromatic motif but have different residue compositions and somewhat different binding properties. SS-31 has emerged as the most extensively characterized member of the family, with the most published preclinical data and the clearest mechanistic account, but investigators interested in structure-activity relationships within the SS series may find the related peptides useful comparators in mechanistic studies.
The combination of a defined molecular mechanism, membrane-potential-independent mitochondrial accumulation, accessibility as a chemically synthesized reagent, and a robust preclinical literature gives SS-31 a comparatively strong foundation among mitochondrial-targeted research tools. This profile makes it particularly useful as a positive control in studies of cardiolipin biology and as a probe of mitochondrial contributions to broader cellular phenotypes.
Research Considerations for Laboratory Use
For investigators working with SS-31 in laboratory settings, the peptide’s high aqueous solubility and well-defined mechanism simplify experimental design. Lyophilized material should be stored at −20°C or below prior to reconstitution. Reconstituted solutions are typically prepared in sterile bacteriostatic water or 0.9% saline. The compound does not require organic carrier solvents for aqueous preparation, though investigators studying cellular uptake should be aware that the peptide’s amphipathic structure allows it to cross plasma membranes and accumulate in mitochondria without active transport.
Research-grade SS-31 is typically characterized at ≥98% purity by HPLC analysis, with identity confirmed by mass spectrometry (expected molecular weight: 639.79 Da). The presence of the non-canonical Dmt residue and the D-arginine should be verified through mass spectrometric analysis to confirm correct chirality and modification. Lot-specific certificates of analysis (CoAs) documenting purity, water content, residual solvents, and sterility are standard practice for research procurement.
Research Methodology Considerations
Designing rigorous SS-31 experiments requires attention to several methodology considerations that recur across the published literature. The peptide’s mitochondrial accumulation, cardiolipin-binding mechanism, and applications across multiple tissue systems impose specific demands on assay selection, dose-ranging, and characterization.
Assay Selection and Readouts
The most commonly reported readouts in SS-31 mechanistic work are mitochondrial respiration assays (Seahorse extracellular flux analysis, Oroboros high-resolution respirometry), ATP production assays, cytochrome c peroxidase activity measurements, cardiolipin peroxidation product analysis (e.g., monolysocardiolipin and oxidized cardiolipin species by mass spectrometry), and electron microscopy of mitochondrial cristae architecture. Functional readouts at the tissue level include echocardiography for cardiac studies, renal function parameters (creatinine, blood urea nitrogen, glomerular filtration rate) for renal studies, and behavioral or histopathological endpoints for neural studies.
Animal Models
Murine and rat models dominate the in vivo SS-31 literature. Commonly cited models include murine renal ischemia-reperfusion (unilateral or bilateral renal artery clamp), murine and rat myocardial ischemia-reperfusion (left anterior descending coronary artery ligation), cerebral artery occlusion models, and aging cohorts of various strains. Larger-animal work in dogs and pigs has been published for heart failure investigations. Cross-species comparisons should account for differences in mitochondrial density and cardiolipin composition across tissue types and species, which can influence the magnitude of observed effects.
Dose-Ranging and Pharmacokinetics
Reported in vivo doses in murine and rat work typically fall in a narrow range determined by the peptide’s high mitochondrial affinity. In vitro concentrations in cell-culture systems are typically in the nanomolar-to-low-micromolar range. The D-arginine modification confers improved proteolytic stability relative to natural arginine, but the peptide nonetheless has a finite plasma half-life and is cleared via renal mechanisms. Studies involving chronic dosing should consider repeated administration schedules informed by the published pharmacokinetic literature.
Common Pitfalls
Several methodological pitfalls recur in SS-31 work. First, the peptide’s mitochondrial accumulation is so efficient that effective intramitochondrial concentrations can exceed the nominal cytosolic concentration by orders of magnitude — confounding interpretation of concentration-response relationships if intramitochondrial accumulation is not directly measured. Second, the cardiolipin-binding interaction can be saturable in models with low cardiolipin content, leading to non-linear concentration-effect relationships. Third, the peptide’s antioxidant-like properties at high concentrations can produce reductive stress, complicating interpretation of mechanistic studies in systems where mitochondrial reactive species are themselves signaling molecules.
Characterization Standards
Beyond ≥98% HPLC purity, rigorous SS-31 work calls for high-resolution mass spectrometry to confirm molecular weight and modifications, chiral HPLC or NMR analysis to confirm D-arginine stereochemistry, and amino acid analysis to confirm composition. The Dmt residue requires specialized synthesis and confirmation steps that are not always available in standard peptide manufacturing — investigators should verify Dmt incorporation by mass spectrometry. Stability monitoring across multi-month studies, particularly for reconstituted aliquots, is good practice.
Controls and Comparators
Useful control conditions include vehicle-only, a structurally related but cardiolipin-non-binding peptide (such as scrambled-sequence variants), and a non-mitochondrially-targeted antioxidant control. For mechanistic studies of cardiolipin-binding-dependent effects, peptides lacking the Dmt residue or with substitutions in the cationic positions provide informative comparisons. Tissue-specific cardiolipin synthase or remodeling-enzyme manipulations (e.g., tafazzin manipulation) can isolate the contribution of cardiolipin abundance and composition to observed effects.
Conclusion
SS-31 occupies a distinctive position in mitochondrial research: a small, chemically well-defined tetrapeptide with a published mechanism centered on cardiolipin binding, and an extensive body of preclinical work across renal, cardiac, neural, and aging-related models. The combination of mechanistic clarity, broad tissue applicability, and accessibility as a synthetic reagent has made SS-31 a frequently used research tool for investigators studying mitochondrial bioenergetics and ischemia-reperfusion biology.
For investigators considering SS-31 as a laboratory reagent, the published literature provides a substantial foundation for hypothesis-driven experimentation. As with any compound at the preclinical research stage, conclusions about clinical relevance in human systems must be drawn cautiously from preclinical data, and experimental designs should incorporate appropriate controls and validated endpoints relevant to mitochondrial function. The membrane-potential-independent localization and the cardiolipin-binding mechanism that distinguish SS-31 from other mitochondrial-targeted research compounds give the peptide a particular utility as a probe of cardiolipin biology and as a positive control in studies of mitochondrial bioenergetics across diverse tissue systems.
Frequently Asked Questions
What is the SS-31 peptide?
SS-31 is a synthetic mitochondrial-targeted tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) developed by Hazel Szeto and Peter Schiller. It is named for the Szeto-Schiller peptide series and is the most extensively characterized member. The peptide selectively accumulates in the inner mitochondrial membrane through high-affinity binding to cardiolipin, and is widely used as a research tool in mitochondrial biology.
What research has been conducted on the SS-31 peptide?
The SS-31 research literature spans cardiolipin binding and biophysics, mitochondrial bioenergetics, ischemia-reperfusion injury models across multiple organ systems (heart, kidney, brain), heart failure and cardiomyopathy models, and aging-associated mitochondrial dysfunction. Foundational mechanistic work was published in the Journal of the American Society of Nephrology in 2013 by Birk and colleagues at Weill Cornell Medical College.
How is the SS-31 peptide used in research settings?
In published preclinical studies, SS-31 has been administered via subcutaneous or intraperitoneal injection in rodent models and added directly to cell culture media for in vitro mitochondrial function studies. The peptide’s ability to cross plasma membranes and accumulate in mitochondria without active transport simplifies many experimental designs. Investigators should consult primary literature for model-specific parameters.
What is the purity standard for research-grade SS-31 peptide?
Research-grade SS-31 is typically characterized at ≥98% purity by HPLC analysis, with identity confirmed by mass spectrometry (expected molecular weight: 639.79 Da). Verification of correct stereochemistry (the D-arginine at the N-terminus) and the presence of the modified 2′,6′-dimethyltyrosine residue is essential. Reputable suppliers provide lot-specific certificates of analysis documenting purity, water content, residual solvents, and sterility.
How does SS-31 target mitochondria without depending on membrane potential?
SS-31 accumulates in the inner mitochondrial membrane through electrostatic and hydrophobic interactions with cardiolipin, a phospholipid expressed almost exclusively in that membrane. Because the interaction depends on cardiolipin rather than on membrane potential, SS-31 localizes to mitochondria even in tissue undergoing severe bioenergetic stress when membrane potential is depolarized — distinguishing it from triphenylphosphonium-conjugated antioxidants that require an intact potential to accumulate.
What is the role of cardiolipin in SS-31’s mechanism of action?
Cardiolipin is a tetra-acyl phospholipid found almost exclusively in the inner mitochondrial membrane. It is required for cristae architecture and supports the assembly and function of multiple respiratory chain components. Under oxidative stress, cardiolipin can bind cytochrome c and convert it into a peroxidase, initiating apoptotic cascades. SS-31 binds cardiolipin with high affinity and disrupts this conversion, preserving cardiolipin integrity and supporting mitochondrial function.
What in vivo models have most commonly been used in SS-31 peptide research?
Murine and rat renal ischemia-reperfusion models, myocardial ischemia-reperfusion models (typically left anterior descending coronary artery ligation), cerebral ischemia models, and aging cohorts are the most frequently reported. Larger-animal heart-failure studies in dogs and pigs have also been published. Each model engages distinct aspects of mitochondrial biology, and selection should match the bioenergetic question under investigation.
How does SS-31 compare to other mitochondrial-targeted research compounds?
Compared with TPP-conjugated antioxidants such as MitoQ, SS-31’s cardiolipin-binding mechanism makes it independent of membrane potential — a key distinction in ischemia or depolarization contexts. Compared with mitochondrial-derived signaling peptides such as MOTS-c and humanin, SS-31 is a synthetic compound designed to accumulate in mitochondria from the cytosol, rather than a signaling peptide released from mitochondria. These compounds are complementary rather than interchangeable in research applications.
What endpoints are most informative in SS-31 mitochondrial bioenergetics studies?
The most informative endpoints include high-resolution respirometry (Oroboros or Seahorse), ATP production assays, cytochrome c peroxidase activity, cardiolipin peroxidation product analysis by mass spectrometry, and electron microscopy of cristae architecture. At the tissue level, organ-specific functional readouts such as echocardiography for heart, GFR and creatinine for kidney, and behavioral or histopathological endpoints for neural studies provide complementary information.
What characterization should be expected for research-grade SS-31?
Beyond standard ≥98% HPLC purity and mass spectrometric confirmation of molecular weight, research-grade SS-31 should be characterized for correct D-arginine stereochemistry (by chiral HPLC or NMR), confirmation of the 2′,6′-dimethyltyrosine residue by mass spectrometry, amino acid analysis to verify composition, and water content by Karl Fischer titration. Endotoxin testing is advisable for studies involving immune-cell readouts or in vivo work.
References
- Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. 2013;24(8):1250–1261. PMID: 23813215.
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology. 2014;171(8):2029–2050. PMID: 24117165.
- Zhao K, Zhao GM, Wu D, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. Journal of Biological Chemistry. 2004;279(33):34682–34690. PMID: 15178689.
- Dai DF, Chen T, Szeto H, et al. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. Journal of the American College of Cardiology. 2011;58(1):73–82. PMID: 21620606.
- Szeto HH, Liu S. Cardiolipin-targeted peptides rejuvenate mitochondrial function, remodel mitochondria, and promote tissue regeneration during aging. Archives of Biochemistry and Biophysics. 2018;660:137–148. PMID: 30342885.
- Siegel MP, Kruse SE, Percival JM, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. 2013;12(5):763–771. PMID: 23692570.
- Liu S, Soong Y, Seshan SV, Szeto HH. Novel cardiolipin therapeutic protects endothelial mitochondria during renal ischemia and mitigates microvascular rarefaction, inflammation, and fibrosis. American Journal of Physiology – Renal Physiology. 2014;306(9):F970–F980. PMID: 24553434.
- Sabbah HN, Gupta RC, Kohli S, Wang M, Hachem S, Zhang K. Chronic therapy with a mitochondria-targeting peptide reverses mitochondrial dysfunction in a canine model of advanced heart failure. Circulation: Heart Failure. 2016;9(2):e002206. PMID: 26839394.
- Campbell MD, Duan J, Samuelson AT, et al. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radical Biology and Medicine. 2019;134:268–281. PMID: 30597195.
- Min K, Smuder AJ, Kwon OS, Kavazis AN, Szeto HH, Powers SK. Mitochondrial-targeted antioxidants protect skeletal muscle against immobilization-induced muscle atrophy. Journal of Applied Physiology. 2011;111(5):1459–1466. PMID: 21817113.
- Birk AV, Chao WM, Bracken C, Warren JD, Szeto HH. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. British Journal of Pharmacology. 2014;171(8):2017–2028. PMID: 24134698.
SS-31 is supplied for in vitro and in vivo laboratory research use only. It is not approved for human or veterinary use.
